Recipharm is a pharmaceutical contract development and manufacturing organisation. Recipharm offers manufacturing services for pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development.

Visit Website

Recipharm AB
Box 603
SE-101 32 Stockholm

Phone / Contact

T: + 46 8 602 52 00
E: [email protected]


Recipharm is a large CDMO offering a range of services for solid, liquid, semi-solid, inhalable, injectable and ophthalmic dosage forms, via four business segments:

  1. Advanced Drug Delivery Systems, which develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices
  2. Sterile Manufacturing, which manufactures sterile products (including using lyophilisation and blow-fill-seal (BFS) technologies)
  3. Solid and Other Manufacturing, which manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products
  4. Development & Licensing, which provides pharmaceutical development services, and manages Recipharm’s patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (APIs).

Recipharm  was founded in 1995 as Recip, and became Recipharm in 2001. It has been privately owned by Swedish private equity firm EQT IX since March 2021, when it delisted from the Stockholm Stock Exchange.

Articles by Recipharm